Real World Evaluation of Teclistamab: A Focus on Infections in Patients With Relapsed Refractory Multiple Myeloma (RRMM)

被引：0
|
作者：
Asoori, Sireesha [1 ]
Martin, Thomas [1 ]
Wolf, Jeffrey [1 ]
Chung, Alfred [1 ]
Arora, Shagun [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CT; teclistamab; relapsed refractory multiple myeloma; infections;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT-630
引用
收藏
页码：S536 / S537
页数：2
相关论文
共 50 条
  • [1] Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)
    Maringanti, Sireesha Asoori
    Lin, Yi
    Estritis, Stathis
    Martinez-Lopez, Joaquin
    Bansal, Radhika
    Fotiou, Despina
    Corona, Magdalena
    Chhabra, Saurabh
    Brunaldi, Larissa
    Corraes, Andre De Menezes Silva
    Parrondo, Ricardo
    Kapoor, Prashant
    Ailawadhi, Sikander
    Mas, Reyes
    Tamayo, Andrea
    Dimopoulos, Meletios
    Durie, Brian
    Martin, Thomas
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S506 - S507
  • [2] Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
    Asoori, Sireesha
    Popat, Rakesh
    Martinez-Lopez, Joaquin
    Kastritis, Efstathios
    Brunaldi, Larissa
    Bansal, Radhika
    Corraes, Andre De Menezes Silva
    Yong, Kwee
    Mactier, Catriona
    Corona, Magdalena
    Saez Marin, Adolfo Jesus
    Fotiou, Despina
    Dimopoulos, Meletios Athanasios
    Chhabra, Saurabh
    Ailawadhi, Sikander
    Parrondo, Ricardo
    Martin, Thomas
    Durie, Brian G. M.
    Lin, Yi
    [J]. BLOOD, 2023, 142
  • [3] Safety and Efficacy of Teclistamab in Patients with Relapsed/ Refractory Multiple Myeloma: A Real-World Experience
    Dima, Danai
    Davis, James A.
    Ahmed, Nausheen
    Jia, Xuefei
    Sannareddy, Aishwarya
    Shaikh, Hira
    Shune, Leyla
    Kaur, Gurbakhash
    Khouri, Jack
    Afrough, Aimaz
    Strouse, Christopher
    Lochner, Jonathan
    Mahmoudjafari, Zahra
    Raza, Shahzad
    Valent, Jason
    Anderson Jr, Larry D.
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    [J]. TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (03): : 308.e1 - 308.e13
  • [4] Teclistamab in Relapsed or Refractory Multiple Myeloma
    Hindie, Elif
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (18): : 1721 - 1723
  • [5] Teclistamab in Relapsed or Refractory Multiple Myeloma
    Moreau, Philippe
    Garfall, Alfred L.
    van de Donk, Niels W. C. J.
    Nahi, Hareth
    San-Miguel, Jesus F.
    Oriol, Albert
    Nooka, Ajay K.
    Martin, Thomas
    Rosinol, Laura
    Chari, Ajai
    Karlin, Lionel
    Benboubker, Lotfi
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Popat, Rakesh
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Sidana, Surbhi
    Delforge, Michel
    Pei, Lixia
    Trancucci, Danielle
    Verona, Raluca
    Girgis, Suzette
    Lin, Shun X. W.
    Olyslager, Yunsi
    Jaffe, Mindy
    Uhlar, Clarissa
    Stephenson, Tara
    Van Rampelbergh, Rian
    Banerjee, Arnob
    Goldberg, Jenna D.
    Kobos, Rachel
    Krishnan, Amrita
    Usmani, Saad Z.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (06): : 495 - 505
  • [6] Real-world schedule de-escalation of teclistamab in patients with relapsed/refractory multiple myeloma
    Tan, Carlyn Rose Co
    Derkach, Andriy
    Maclachlan, Kylee
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David J.
    Landau, Heather Jolie
    Giralt, Sergio
    Lesokhin, Alexander M.
    Korde, Neha
    Lin, Dee
    Wu, Bingcao
    Fowler, Jessica
    Fernandez, Mariana
    Usmani, Saad Zafar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
    Krishnan, Amrita Y.
    Nooka, Ajay K.
    Chari, Ajai
    Garfall, Alfred L.
    Martin, Thomas G.
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Londhe, Anil
    Pei, Lixia
    Eric, Ammann
    Kobos, Rachel
    Smit, Jennifer
    Parekh, Trilok V.
    Slavcev, Mary
    Usmani, Saad Zafar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] DURATION OF THERAPY IN US PATIENTS TREATED FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE REAL-WORLD
    Romanus, D.
    Raju, A.
    Yong, C.
    Seal, B.
    Farrelly, E.
    Noga, S.
    Jhaveri, M.
    Labotka, R.
    Blazer, M.
    Parameswaran, H.
    [J]. HAEMATOLOGICA, 2016, 101 : 538 - 539
  • [9] REAL-WORLD EXPERIENCE OF LENALIDOMIDE/DEXAMETHASONE TREATMENT FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM) PATIENTS
    Tognazzi, L.
    Rivolti, E.
    Quaresima, M.
    Labbozzetta, S.
    Gamberi, B.
    Merli, F.
    [J]. HAEMATOLOGICA, 2017, 102 : 137 - 137
  • [10] Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
    Dima, Danai
    Davis, James A.
    Ahmed, Nausheen
    Sannareddy, Aishwarya
    Shaikh, Hira
    Mahmoudjafari, Zahra
    Khouri, Jack
    Kaur, Gurbakhash
    Strouse, Christopher
    Valent, Jason
    Larry, Anderson D., Jr.
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    [J]. BLOOD, 2023, 142
12345